An article published this year in “PlosOne” using one of our products, “PerCP Mouse anti-Human CD4”, by our customers from the Immunology Department, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain, In how Levels of anti-CMV antibodies are modulated by the frequency and intensity of virus reactivations in kidney transplant patients. Congrats and Thanks.
Summay:
Anti-CMV (cytomegalovirus) antibody
titers are related to immune alterations and increased risk of mortality. To
test whether they represent a marker of infection history, we analyzed the
effect of viral reactivations on the production of specific antibodies in
kidney transplant patients. We quantified CMV-DNAemia and antibody titers in 58
kidney transplant patients before transplantation and during a follow-up of 315
days (standard deviation, SD: 134.5 days). In order to calculate the intensity
of the infection, we plotted the follow-up time of the infection on the x-axis
and the number of DNA-CMV copies on the y-axis and calculated the area under
the curve (CMV-AUC). The degree of T-lymphocyte differentiation was analyzed
with flow cytometry, the cells were labelled with different monoclonal
antibodies in order to distinguish their differentiation state, from naive
T-cells to senescent T-cells. Peak viremia was significantly higher in patients
experiencing a primary infection (VI) compared to patients experiencing viral
reactivation (VR). Our data indicate that the overall CMV viral load over the
course of a primary infection is significantly higher than in a reactivation of
a previously established infection. Whereas patients who experienced an episode
of CMV reactivation during the course of our observation showed increased
levels of CMV-specific antibodies, patients who did not experience CMV
reactivation (WVR) showed a drop in CMV antibody levels that corresponds to an
overall drop in antibody levels, probably due to the continuing
immunosuppression after the renal transplant. We found a positive correlation
between the CMV viremia over the course of the infection or reactivation and
the CMV-specific antibody titers in the examined patients. We also observed a
positive correlation between anti-CMV titers and T-cell differentiation. In
conclusion, our data show that anti-CMV antibody titers are related to the
course of CMV infection in kidney transplant patients.
Fig. Differentiation status of CD4+ and CD8+ T-lymphocytes according to CMV
serostatus and anti-CMV antibody levels.
(A)
Distribution of CD4+ and CD8+ T-cells into CD28+CD27+ (less-differentiated) and
CD28nullCD27null (more-differentiated) subsets
according to patients CMV serostatus. (B) Distribution of CD4+ and CD8+ T-cells
into CD28+CD27+ (less-differentiated), CD28+CD27null/CD28nullCD27+
(intermediate), and CD28nullCD27null (more-differentiated)
subsets was related to anti-CMV antibody titers in CMV-seropositive patients (n
= 24). Expression of CD28+ and CD27+ was analyzed by flow cytometry in gated
CD3+CD4+ T-cells and in CD3+CD8+ T-cells. Linear regression coefficients
adjusted by age and corresponding p-values are indicated
Reference:
Product link:
PerCP Mouse anti-Human
CD4
No comments:
Post a Comment